Merck’s Mavenclad (Cladribine Tablets) Approved for Relapsing-Remitting Multiple Sclerosis in Canada

December 3, 2017

Responsive image

DARMSTADT, Germany, December 4, 2017 /PRNewswire/ —

First oral short-course treatment for relapsing- remitting multiple sclerosis (RRMS) now approved in Canada, which has one of the highest rates of MS in the world[1]
Mavencladhas shown sustained clinical efficacy with a…

Category: Precious Metals